SLC45A4 is Involved in Malignant Progression of Ovarian Cancer Through Glycolytic Metabolic Reprogramming

Overview

Journal Sci Rep

Specialty Science

Date 2024 Oct 3

PMID 39363015

Authors

Yuance Xu

Xiahui Han

Shijing You

Wei Zhu

Mingyun Zhang

Changyu Lu

Junqi He

Qin Yao

Affiliations

Soon will be listed here.

Abstract

Tumor cells promote malignant behaviors such as proliferation, invasion, and metastasis of cancer cells through glucose metabolic reprogramming, but the role of the H-dependent sugar cotransporter SLC45A4 in regulating metabolic reprogramming in ovarian cancer (OC) remains largely unknown. This study aimed to investigate the effects of SLC45A4 silencing on the transcriptome spectrum of ovarian cancer cells (OCC), glucose uptake, lactic acid production, intracellular ATP levels, and the expression and activity of HIF-α glycolysis signaling pathway. The results showed that SLC45A4 is overexpressed in OC and its elevated expression correlates with adverse clinical outcomes in OC patients. Silencing of SLC45A4 significantly inhibited the proliferation, invasion, and metastasis of OCC by suppressing glucose uptake and glycolysis, and it also reduced the expression of HIF-α glycolysis signaling pathway in OC tissues. In vivo experiments using shRNA to knock down SLC45A4 in xenograft models in nude mice demonstrated a significant inhibition of tumor growth. These findings suggest that SLC45A4 silencing can restrain the malignant progression of OC by inhibiting glucose uptake in OCC and affecting the reprogramming of glycolytic energy metabolism, indicating that SLC45A4 may serve as a potential therapeutic target for OC intervention.

References

Lheureux S, Gourley C, Vergote I, Oza A . Epithelial ovarian cancer. Lancet. 2019; 393(10177):1240-1253. DOI: 10.1016/S0140-6736(18)32552-2. View

Cortez A, Tudrej P, Kujawa K, Lisowska K . Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2017; 81(1):17-38. PMC: 5754410. DOI: 10.1007/s00280-017-3501-8. View

Vitavska O, Wieczorek H . The SLC45 gene family of putative sugar transporters. Mol Aspects Med. 2013; 34(2-3):655-60. DOI: 10.1016/j.mam.2012.05.014. View

Le L, Escobar I, Ho T, Lefkovith A, Latteri E, Haltaufderhyde K . SLC45A2 protein stability and regulation of melanosome pH determine melanocyte pigmentation. Mol Biol Cell. 2020; 31(24):2687-2702. PMC: 7927184. DOI: 10.1091/mbc.E20-03-0200. View

Park J, Talukder A, Lim S, Kim K, Pan K, Melendez B . SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunol Res. 2017; 5(8):618-629. PMC: 6087543. DOI: 10.1158/2326-6066.CIR-17-0051. View

Kalos M, Askaa J, Hylander B, Repasky E, Cai F, Vedvick T . Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate. 2004; 60(3):246-56. DOI: 10.1002/pros.20043. View

Bartolke R, Heinisch J, Wieczorek H, Vitavska O . Proton-associated sucrose transport of mammalian solute carrier family 45: an analysis in Saccharomyces cerevisiae. Biochem J. 2014; 464(2):193-201. DOI: 10.1042/BJ20140572. View

OToole E, Kelsell D, Caterina M, de Brito M, Hansen D, Hickerson R . Pachyonychia Congenita: A Research Agenda Leading to New Therapeutic Approaches. J Invest Dermatol. 2023; 144(4):748-754. DOI: 10.1016/j.jid.2023.10.030. View

Xie J, Ruan S, Zhu Z, Wang M, Cao Y, Ou M . Database mining analysis revealed the role of the putative H/sugar transporter solute carrier family 45 in skin cutaneous melanoma. Channels (Austin). 2021; 15(1):496-506. PMC: 8331014. DOI: 10.1080/19336950.2021.1956226. View

10.

Gyorffy B, Lanczky A, Szallasi Z . Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2):197-208. DOI: 10.1530/ERC-11-0329. View

11.

Lanczky A, Gyorffy B . Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J Med Internet Res. 2021; 23(7):e27633. PMC: 8367126. DOI: 10.2196/27633. View

12.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

13.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

14.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

15.

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View

16.

Cannizzaro M, Jarosova J, De Paepe B . Relevance of solute carrier family 5 transporter defects to inherited and acquired human disease. J Appl Genet. 2019; 60(3-4):305-317. DOI: 10.1007/s13353-019-00502-1. View

17.

Garibsingh R, Schlessinger A . Advances and Challenges in Rational Drug Design for SLCs. Trends Pharmacol Sci. 2019; 40(10):790-800. PMC: 7082830. DOI: 10.1016/j.tips.2019.08.006. View

18.

Vander Heiden M, DeBerardinis R . Understanding the Intersections between Metabolism and Cancer Biology. Cell. 2017; 168(4):657-669. PMC: 5329766. DOI: 10.1016/j.cell.2016.12.039. View

19.

Barron C, Bilan P, Tsakiridis T, Tsiani E . Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016; 65(2):124-39. DOI: 10.1016/j.metabol.2015.10.007. View

20.

Corbet C, Feron O . Tumour acidosis: from the passenger to the driver's seat. Nat Rev Cancer. 2017; 17(10):577-593. DOI: 10.1038/nrc.2017.77. View